We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$250M
1-Year Est. Return
77.6%
This Fund
S&P 500
This Quarter
Est. Return
+31.91%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$158M
AUM Growth
+$48.6M
(+44%)
Cap. Flow
+$17.3M
Cap. Flow
% of AUM
10.96%
Top 10 Holdings %
Top 10 Hldgs %
69.15%
Holding
41
New
16
Increased
13
Reduced
5
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$6.03M |
| 2 |
Royalty Pharma
RPRX
|
+$5.87M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
+$5.12M |
| 4 |
Zevra Therapeutics
ZVRA
|
+$4.75M |
| 5 |
UroGen Pharma
URGN
|
+$4.16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALIM
Alimera Sciences
ALIM
|
+$19.5M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$9.84M |
| 3 |
Evolus
EOLS
|
+$4.02M |
| 4 |
Aurinia Pharmaceuticals
AUPH
|
+$1.71M |
| 5 |
XOMA
Xoma
XOMA
|
+$1.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KZR
26
DELISTED
Kezar Life Sciences
KZR
| $1.15M | 0.73% |
149,131
+44,086
| +42% | +$266K |
|
27
Adicet Bio
ACET
$84.7M
| $878K | 0.55% |
38,090
| – | – |
|
28
Arcutis Biotherapeutics
ARQT
$3.5B
| $823K | 0.52% |
+88,457
| New | +$873K |
|
|
FNA
29
DELISTED
Paragon 28, Inc.
FNA
| $766K | 0.48% |
+114,724
| New | +$869K |
|
30
Kiora Pharmaceuticals
KPRX
$11.3M
| $741K | 0.47% |
202,400
+2,400
| +1% | +$9.36K |
|
31
PolyPid
PYPD
$83.8M
| $476K | 0.3% |
+138,504
| New | +$498K |
|
|
TSVT
32
DELISTED
2seventy bio
TSVT
| $472K | 0.3% |
100,000
| – | – |
|
33
Myomo
MYO
$38.6M
| $401K | 0.25% |
+100,000
| New | +$414K |
|
34
Aprea Therapeutics
APRE
$7.86M
| $377K | 0.24% |
137,174
| – | – |
|
|
ITOS
35
DELISTED
iTeos Therapeutics
ITOS
| $306K | 0.19% |
+30,000
| New | +$458K |
|
36
Tenax Therapeutics
TENX
$401M
| $173K | 0.11% |
+50,000
| New | +$181K |
|
|
VIRX
37
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $116K | 0.07% |
+500,000
| New | +$183K |
|
|
38
Aurinia Pharmaceuticals
AUPH
$1.93B
| – | – |
-300,000
| Closed | -$1.71M |
|
39
Eton Pharmaceutcials
ETON
$1.34B
| – | – |
-110,000
| Closed | -$362K |
|
|
ALIM
40
DELISTED
Alimera Sciences
ALIM
| – | – |
-3,511,816
| Closed | -$19.5M |
|
Similar funds
ER
FDDB
VM
PF
SCM
CWM
EWM
RA
Stonepine Capital Management's Q3 2024 Portfolio in Review
As of Q3 2024, Stonepine Capital Management held 41 positions worth $158M, up 44% from $110M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Stonepine Capital Management deployed $17.3M of net new capital in Q3 2024, opening 16 new positions and adding to 13 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 55,000 shares worth $6.13M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.
On the sell side, the largest reduction was Revance Therapeutics, Inc., an estimated $9.84M trimmed.
- Stonepine Capital Management's largest Q3 2024 buy was Jazz Pharmaceuticals: 55,000 shares worth $6.13M.
- Stonepine Capital Management added most to Ironwood Pharmaceuticals in Q3 2024, an estimated $5.12M increase.
- Stonepine Capital Management's biggest Q3 2024 reduction was Revance Therapeutics, Inc., cutting an estimated $9.84M.
- Stonepine Capital Management fully exited Alimera Sciences in Q3 2024, selling an estimated $19.5M.
- Stonepine Capital Management's ten largest holdings make up 69% of its $158M portfolio in Q3 2024.
- Stonepine Capital Management opened 16 new positions and closed 3 in Q3 2024.
- Stonepine Capital Management's portfolio value rose 44% quarter-over-quarter to $158M.
Based on Stonepine Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.